Welcome to our dedicated page for Catheter Precision SEC filings (Ticker: VTAK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Catheter Precision, Inc. (VTAK) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including Forms 10‑K, 10‑Q and 8‑K, along with proxy statements and registration statements. As a NYSE American–listed medical device company focused on the cardiac electrophysiology market, Catheter Precision uses these filings to report on its business, financial condition, capital structure, and material events affecting VTAK stock.
Through its periodic reports, such as the annual Form 10‑K and quarterly Forms 10‑Q, Catheter Precision presents audited and interim financial statements, management’s discussion and analysis, and detailed risk factor sections. These documents expand on topics referenced in press releases, including the company’s history of operating losses, its need for additional financing to continue as a going concern, regulatory dependencies for its VIVO and LockeT products, and competitive and operational risks.
Current reports on Form 8‑K capture specific developments, such as reverse stock split implementation, amendments to short‑term promissory notes held by related parties, termination of an at‑the‑market equity offering program, and the release of quarterly financial results. Other 8‑K filings incorporate legal opinions related to registration statements and announcements about regulatory approvals in certain markets.
Definitive proxy statements on Schedule 14A outline matters submitted to stockholders, including proposals to authorize reverse stock splits, increase authorized shares, approve share issuances under NYSE American rules, and ratify the appointment of independent registered public accounting firms. These documents also describe the mechanics of virtual stockholder meetings and voting procedures.
On Stock Titan, AI-powered tools summarize lengthy filings so readers can quickly understand key points from Catheter Precision’s 10‑K, 10‑Q, and 8‑K reports without reading every page. Real-time updates from EDGAR ensure new filings appear promptly, while specialized views highlight items relevant to equity structure changes, financing arrangements, and governance decisions. Users can also review insider-related information disclosed in filings, such as amendments to notes held by executives and affiliated entities, to better understand relationships between management and the company’s capital structure.
Catheter Precision, Inc. reported 2025 results showing revenue growth of 95% year over year but a GAAP net loss of $17.7M. After adding back non-cash items such as intangible asset impairment and debt extinguishment, the company reported a 2025 non-GAAP adjusted net loss of $7.8M.
For Q4 2025, GAAP net loss was $5.3M and non-GAAP adjusted net loss was $3.5M. Management highlighted progress in commercializing its VIVO and LockeT cardiac devices and, after year-end, completed the acquisition of Flyte, a regional air mobility company, creating two operating platforms in medical devices and aviation.
The company also disclosed risk factors, including that it does not have sufficient liquidity to fund operations through fiscal 2026 without additional financing or a strategic transaction, and outlined numerous operational, regulatory, and integration risks around its products and the Flyte expansion.
Catheter Precision, Inc. outlines its cardiac electrophysiology-focused business built around the VIVO 3D mapping system and LockeT vascular closure device, alongside new subsidiaries Cardionomix and KardioNav targeting heart failure and device-integrated mapping technologies. The company reports a going concern uncertainty, highlighting an accumulated deficit and reliance on external financing after raising approximately $4.9 million in 2025. As of March 20, 2026, it had 2,692,473 shares outstanding and a June 2025 public float valued at about $3.9 million. Management plans to grow by expanding VIVO indications, building clinical evidence for LockeT, leveraging international approvals, and selectively pursuing complementary technologies, but warns of significant regulatory, reimbursement, competition, and capital-raising risks.
Catheter Precision, Inc. reported that Chairman and CEO David A. Jenkins received a grant of options to buy 40,000 shares of common stock. The options have an exercise price of $1.15 per share, expire on March 26, 2036, and vest 100% 180 days after the grant date.
Catheter Precision, Inc. reported that its Chief Financial Officer, Philip J. Anderson, received a grant of stock options covering 40,000 shares of common stock. The options have an exercise price of $1.15 per share and expire on March 26, 2036.
The options were awarded as a compensation grant and vest 100% on the 180-day anniversary of the grant date. Following this grant, Anderson holds derivative securities representing rights to acquire 40,000 shares of Catheter Precision common stock through these options.
Catheter Precision, Inc. director Arno Andrew received a grant of stock options as part of his compensation. The award covers 40,000 options to buy common stock at an exercise price of $1.15 per share, expiring on March 26, 2036. The options vest 100% on the 180-day anniversary of the grant date, and following this grant he holds 40,000 derivative securities of this type directly.
Catheter Precision, Inc. director James Joseph Caruso received a grant of options to buy 40,000 shares of common stock. The options have an exercise price of $1.15 per share and expire on March 26, 2036. According to the grant terms, the options vest 100% on the 180-day anniversary of the grant date.
Catheter Precision, Inc. director Martin J. Colombatto received a grant of stock options on Common Stock. The award covers 40,000 options with an exercise price of $1.15 per share, expiring on March 26, 2036. The options vest 100% on the 180-day anniversary of the grant date, and following this grant he holds 40,000 options directly.
Catheter Precision, Inc. is asking stockholders at an April 15, 2026 virtual special meeting to approve several financing-related proposals and a potential reverse stock split. Stockholders of record as of March 9, 2026, when 2,357,127 common shares were outstanding, may vote.
The company seeks approval under NYSE American rules for common shares issuable from new Series C, Series D and Series J preferred stock structures and a reduced conversion price on existing Series B preferred stock. These preferred series could, at specified floor prices and assuming full participation, convert into large numbers of common shares, including up to 252,047,623 shares from Series C, 31,508,572 from Series D and 6,083,005 from Series J, plus an increase in Series B conversion capacity from 335,214 to 1,252,344 shares.
Stockholders are also being asked to authorize a reverse stock split of common stock at a ratio between 1‑for‑2 and 1‑for‑100, at the board’s discretion within one year, primarily to help the company maintain NYSE American listing standards and potentially broaden institutional interest.
Catheter Precision, Inc. is asking stockholders to approve six proposals at a Special Meeting on April 15, 2026, primarily to authorize multiple preferred‑stock issuances and related conversions and to permit a board‑determined reverse stock split.
The company seeks approval to issue Series C, Series D, Series J and reduced‑price Series B convertible preferred stock that, if converted at stated floors or terms, could add up to 252,047,623 (Series C), 31,508,572 (Series D), 6,083,005 (Series J) and 1,252,344 (Series B) shares of Common Stock. Shares outstanding were 2,357,127 as of the record date (March 9, 2026).
The board also asks authority to effect a reverse stock split at a ratio between 1‑for‑2 and 1‑for‑100, to be chosen by the board if approved. Record date and registration/filing mechanics are described in the proxy materials.
Catheter Precision, Inc. is raising capital through a private placement of preferred stock and using part of the funds to buy aviation-related assets. The company agreed to sell 1,853 shares of Series C-1 Convertible Preferred Stock for $1,853,000, initially convertible into up to 1,295,805 common shares at $1.43 per share, with future conversion prices tied to trading levels and subject to a floor that the company may waive. Investors also committed to buy additional Series C-2 and C-3 preferred shares for $1,853,000 each, and may later purchase up to $35,559,326 of Series C-4 Preferred Stock, all with variable conversion prices based on 80% of market measures and floor-price conditions. The company plans to use net proceeds for working capital, restructuring its legacy catheter business, settling legacy liabilities, simplifying its capital structure, and cutting operating expenses.
In a linked transaction, Catheter Precision agreed to acquire 80.02% of Fly Flyte, Inc. and all membership interests of Ponderosa Air, LLC from Creatd, Inc. for total consideration of $11,554,827, consisting of $776,827 cash at closing, a $5,000,000 zero‑coupon note due by December 15, 2026, and 5,778 shares of Series D Convertible Preferred Stock with an aggregate stated value of $5,778,000. Issuance and conversion of multiple preferred series depend on stockholder approval under NYSE American Section 713 and effectiveness of SEC resale registration statements. The company also amended its preferred stock designations to increase authorized Series C‑1 shares and granted registration rights for resale of common shares underlying the preferred stock.